One-Year Follow-Up Of Health-Related Quality Of Life In The Swedish Predix Her 2 Trial, Evaluating Docetaxel, Trastuzumab Sc, Pertuzumab Versus Trastuzumab Emtansine As Neoadjuvant Treatment Of Her2 Positive Breast Cancer.

Yvonne Brandberg,Theodoros Foukakis,Anne Andersson,Judith Bjohle,Ana Bosch,Lena Carlsson,Zakaria Einbeigi,Hanna Fredholm,Erika Isaksson-Friman,Mats Hellstrom,Hemming Johansson,Tobias Lekberg,Henrik Lindman,Jonas C. S. Bergh,Thomas Hatschek

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览67

暂无评分

摘要

590Background: Neoadjuvant therapy combining docetaxel, trastuzumab and pertuzumab (DTP) was compared to trastuzumab emtansine (T-DM1) in the randomised phase II PREDIX HER2 trial. Patients, ≥18 ye...

查看译文

关键词

positive breast cancer,breast cancer,neoadjuvant treatment,trastuzumab sc,one-year,health-related

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要